Compare Invesco S&P 500 Low Volatility ETF (SPLV) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 Low Volatility ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? Invesco S&P 500 Low Volatility ETF trades at $73.8 (market cap $7.06B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Invesco S&P 500 Low Volatility ETF is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Invesco S&P 500 Low Volatility ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco S&P 500 Low Volatility ETF for 124 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SPLV | TVTX | |
|---|---|---|
Market Cap | $7.06B | $4.88B |
Volume | 1,461,921 | 1,668,577 |
52-Week High | $77.97 | $67.52 |
52-Week Low | $70.30 | $26.79 |
Typical Hold Time | 124 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPLV trades at $72.98, up 0.26% with a bullish technical signal from moving averages, though oscillators show neutral momentum. The ETF's sector allocation to utilities and real estate has lagged the broader market, returning 5% versus the S&P 500's 17% year-to-date. Recent dividend payments of $0.14 provide income stability amid market volatility.
Outlook remains cautious as growth-adjusted valuations appear stretched at 19.5x P/E. Risks include sector concentration and macroeconomic pressures, but SPLV offers defensive exposure during market uncertainty. The neutral analyst stance reflects balanced near-term prospects between stability benefits and performance headwinds.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
